epoetin alfa

Generic Name: epoetin alfa

Clinical Trials

EVR and EPO for Liver Transplant Tolerance

Phase 1

Not yet recruiting

Conditions: Liver Transplant

Interventions: Drug: Everolimus
Drug: Epoetin alfa

First Posted Date: 2025-02-18

Last Posted Date: 2025-03-14

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Target Recruit Count: 20

Registration Number: NCT06832189

Locations: 🇺🇸
University of California San Francisco School of Medicine, San Francisco, California, United States
🇺🇸
Northwestern University Feinberg School of Medicine, Chicago, Illinois, United States
🇺🇸
University of Pennsylvania Medical Center, Philadelphia, Pennsylvania, United States

A Retrospective Study to Describe Real-World Treatment Patterns and Clinical Outcomes Among Patients With Myelodysplastic Syndromes

Withdrawn

Conditions: Myelodysplastic Syndromes (MDS)

Interventions: Drug: Epoetin Alfa
Drug: Luspatercept

First Posted Date: 2024-08-30

Last Posted Date: 2024-10-09

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 86

Registration Number: NCT06581055

Locations: 🇨🇳
National Taiwan University Hospital (NTUH), Taipei, Taiwan

ELEMENT-MDS: A Study to Compare the Efficacy and Safety of Luspatercept in Participants With Myelodysplastic Syndrome (MDS) and Anemia Not Receiving Blood Transfusions

Phase 3

Recruiting

Conditions: Myelodysplastic Syndromes

Interventions: Biological: Luspatercept
Biological: Epoetin Alfa

First Posted Date: 2023-07-18

Last Posted Date: 2025-05-09

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 360

Registration Number: NCT05949684

Locations: 🇺🇸
Community Cancer Institute, Clovis, California, United States
🇺🇸
John Muir Medical Center - Concord Campus, Concord, California, United States
🇺🇸
Compassionate Cancer Care Medical Group, Fountain Valley, California, United States

and more 165 locations

Hydroxyurea and EPO in Sickle Cell Disease

Phase 1

Completed

Conditions: Anemia, Sickle Cell
Sickle Cell Disease

Interventions: Drug: Hydroxyurea
Drug: Epoetin Alfa

First Posted Date: 2022-07-11

Last Posted Date: 2025-04-17

Lead Sponsor: Julia Xu

Target Recruit Count: 15

Registration Number: NCT05451940

Locations: 🇺🇸
UPMC, Pittsburgh, Pennsylvania, United States
🇳🇬
Lagos University Teaching Hospital, Lagos, Nigeria

Impact of Erythropoietin on Hematological Adaptations and Physical Performance

Phase 4

Completed

Conditions: Exercise-Induced Anemia
Physical Performance

Interventions: Drug: Epoetin Alfa

First Posted Date: 2021-10-14

Last Posted Date: 2025-04-18

Lead Sponsor: United States Army Research Institute of Environmental Medicine

Target Recruit Count: 8

Registration Number: NCT05078138

Locations: 🇺🇸
US Army Research Institute of Environmental Medicine, Natick, Massachusetts, United States

Desidustat in the Treatment of Anemia in CKD on Dialysis Patients

Phase 3

Completed

Conditions: Chronic Kidney Disease Stage 5 on Dialysis

Interventions: Drug: Desidustat Oral Tablet
Drug: Epoetin Alfa

First Posted Date: 2020-01-02

Last Posted Date: 2021-11-24

Lead Sponsor: Zydus Lifesciences Limited

Target Recruit Count: 392

Registration Number: NCT04215120

Locations: 🇮🇳
Karnavati Hospital Pvt.Ltd, Ahmedabad, Gujarat, India
🇮🇳
Chopda Medicare & Research Centre Pvt. Ltd, Nashik, Maharashtra, India
🇮🇳
Star Hospital, Hyderabad, Telangana, India

and more 4 locations

Evaluate the Efficacy and Safety of HIF-PHI for the Treatment of Anemia and Risks of Cardiovascular and Cerebrovascular Events in ESRD Newly Initiated Dialysis Patients

Phase 4

Not yet recruiting

Conditions: Anemia in Incident Dialysis Patients

Interventions: Drug: Epoetin Alfa
Drug: HIF-PHI

First Posted Date: 2019-10-21

Last Posted Date: 2021-05-25

Lead Sponsor: Second Xiangya Hospital of Central South University

Target Recruit Count: 400

Registration Number: NCT04134026

Locations: 🇨🇳
Department of Nephrology, Second Xiangya Hospital, Central South University, Changsha, Hunan, China

Study to Evaluate the Pharmacokinetics, Pharmacodynamics, and Safety of Vadadustat in Hemodialysis Subjects With Anemia Associated With Chronic Kidney Disease

Phase 1

Completed

Conditions: Anemia Associated With Chronic Kidney Disease

Interventions: Drug: Vadadustat
Drug: Darbepoetin alfa
Drug: Epoetin alfa

First Posted Date: 2019-06-19

Last Posted Date: 2020-09-16

Lead Sponsor: Akebia Therapeutics

Target Recruit Count: 46

Registration Number: NCT03992066

Locations: 🇺🇸
Research Site, Chattanooga, Tennessee, United States

Study of Vadadustat in Hemodialysis Participants With Anemia Switching From Epoetin Alfa

Phase 2

Completed

Conditions: Anemia
Dialysis-dependent Chronic Kidney Disease

Interventions: Drug: Vadadustat
Drug: Vadadustat TIW
Drug: Epoetin Alfa

First Posted Date: 2019-01-10

Last Posted Date: 2022-09-29

Lead Sponsor: Akebia Therapeutics

Target Recruit Count: 175

Registration Number: NCT03799627

Locations: 🇺🇸
Research Site, Wauwatosa, Wisconsin, United States
🇺🇸
Research Site #2, Minneapolis, Minnesota, United States
🇺🇸
Research Site #1, Minneapolis, Minnesota, United States

A Study to Compare the Efficacy and Safety of Luspatercept (ACE-536) Versus Epoetin Alfa for the Treatment of Anemia Due to IPSS-R Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes (MDS) Participants Who Require Red Blood Cell Transfusions and Are ESA Naïve

Phase 3

Active, not recruiting

Conditions: Myelodysplastic Syndromes

Interventions: Drug: Luspatercept
Drug: Epoetin alfa

First Posted Date: 2018-09-24

Last Posted Date: 2024-11-20

Lead Sponsor: Celgene

Target Recruit Count: 363

Registration Number: NCT03682536

Locations: 🇺🇸
Local Institution - 114, Salt Lake City, Utah, United States
🇺🇸
Local Institution - 107, Berkeley, California, United States
🇺🇸
Local Institution - 115, San Diego, California, United States

and more 223 locations

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy